Seattle Genetics reported a third-quarter net loss of $21.8 million, or $0.27 per share, up from $14.6 million, or $0.22 per share, in the same period last year.

Share story

Seattle Genetics reported a third-quarter net loss of $21.8 million, or $0.27 per share, up from $14.6 million, or $0.22 per share, in the same period last year.

The Bothell biotechnology company’s expenses rose on expanded clinical development and manufacturing and higher staff costs.

Revenues climbed to $8.1 million, from $4.6 million, on milestone payments from research partnerships with Genentech and others.